Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley

Anyone looking to see why investment bankers love big time M&A so much should check out Bristol-Myers Squibb’s new SEC filing Thursday evening.

In the leadup to its megamerger with Celgene, the pharma giant has been peppered by a slate of lawsuits from unhappy investors. And to settle one that threatened to possibly delay their deal— now facing a crucial shareholder vote next week that Bristol-Myers is widely expected to win — the Bristol-Myers team agreed to spell out the $187 million-plus in fees they’re paying to Morgan Stanley, which offered their opinion on the fairness of the buyout pact.